This article was originally published in The Gray Sheet
Myriad Genetic's breast and ovarian cancer genetic predisposition test is used in CLIA laboratories. It is not a CLIA-waived test, as was reported (1"The Gray Sheet" Sept. 16, 2002, p. 20)...
You may also be interested in...
Myriad Genetics will concentrate direct-to-consumer advertising in Atlanta and Denver for its BRACAnalysis breast and ovarian cancer genetic predisposition testing service as the firm moves beyond physician education as a sole means of promotion
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.